Neoadjuvant Chemotherapy with FOLFOX4 Regimen to Treat Advanced Gastric Cancer Improves Survival without Increasing Adverse Events: A Retrospective Cohort Study from a Chinese Center
Table 1
Patient demographics and tumor characteristics.
Items
Neoadjuvant group ()
Adjuvant group ()
value*
Median age (yr) (range)
58 (34–79)
57 (31–80)
0.760
Gender: (%)
Male
15 (65.2)
22 (62.9)
0.855
Female
8 (34.8)
13 (37.1)
Anatomic location: (%)
Proximal
4 (17.4)
3 (8.6)
0.490
Body
7 (30.4)
9 (25.7)
Distal
12 (52.2)
23 (65.7)
Tumor grade: (%)
Well/moderately differentiated
6 (26.1)
8 (22.8)
0.701
Poorly differentiated
11 (47.8)
20 (57.1)
Mucinous/signet ring cell cancer
4 (17.4)
6 (17.2)
Others
2 (8.7)
1 (2.9)
Pretreatment clinical T-stage (CT): (%)
Stage 3
17 (73.9)
28 (80.0)
0.587
Stage 4
6 (26.1)
7 (20.0)
Comparisons for categorical variables performed using chi-square test.
